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The regulatory immediate-early (IE) protein pp89 of murine cytomegalovirus induces CD8+ T lymphocytes
that protect against lethal murine cytomegalovirus infection. The IE1 epitope is the only epitope of pp89 that
is recognized by BALB/c cytolytic T lymphocytes (CTL). Using synthetic peptides, the optimal and minimal
antigenic sequences of the TEl epitope have been defined. To evaluate the predictive value of data obtained with
synthetic peptides, recombinant vaccines encoding this single T-celi epitope were constructed using as a vector
the hepatitis B virus core antigen encoded in recombinant vaccinia virus. In infected cells expressing the
chimeric proteins, only IE1 epitope sequences that were recognized as synthetic peptides at concentrations
lower than 10-6 M were presented to CTL. Vaccination of mice with the recombinant vaccinia virus that
encoded a chimeric protein carrying the optimal 9-amino-acid TEl epitope sequence elicited CD8+ T
lymphocytes with antiviral activity and, furthermore, protected against lethal disease. The results thus show
for the first time that recombinant vaccines containing a single foreign nonameric CTL epitope can induce
T-lymphocyte-mediated protective immunity.
Antigenic sequences recognized by cytolytic T lympho-
cytes (CTL) in viral protein antigens can be identified by
using synthetic peptides (23; reviewed in reference 22).
Synthetic peptides also permit definition of the minimal and
optimal sequences that bind to major histocompatibility
complex class I proteins and are recognized by the antigen-
specific T-cell receptor. However, the set of peptides natu-
rally produced in virus-infected cells by processing of viral
proteins may differ substantially from the optimal sequences
defined with synthetic peptides. Presentation to CTL has
been shown recently for epitopes of 13 to 22 amino acids (aa)
expressed from chimeric proteins synthesized in transfected
and infected cells (5, 10, 26). However, chimeric proteins
have failed to induce a T-lymphocyte response in vivo (13).
Knowledge of the features that affect antigenicity and immu-
nogenicity of epitopes expressed from endogenously synthe-
sized proteins is crucial for design of vaccines containing
CTL epitopes.
A need for separate epitopes recognized by helper T
lymphocytes, the nature of the carrier protein, and the length
and antigenic potency of the inserted antigenic sequence
itself may affect the immunogenic potential of recombinant
vaccines. We have addressed these issues in a herpesvirus
model, murine cytomegalovirus (MCMV) infection, in which
a protective antiviral immune response mediated by CD8+ T
lymphocytes is induced by the nuclear viral phosphoprotein
pp89 (11, 17, 18, 20, 25). An epitope of pp89 that is
recognized by CTL clone IEl (15) has been identified and
named the TEl epitope (7). Using synthetic peptides, the
optimal antigenic sequence 168-YPHFMPTNL-176 for CTL
clone IEl has been defined. Shorter peptides such as
PHFMP N and the core HFMPT are also recognized, but
their antigenic potencies are 103- and 106-fold lower, respec-
tively (19).
To examine the predictive value of data obtained with
synthetic peptides for the construction of recombinant T-cell
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epitope vaccines, we inserted DNA sequences encoding IEl
epitope sequences of various lengths and antigenic potencies
into different genetic environments. The capacity of the
resulting chimeric proteins to elicit an effective in vivo
antiviral T-lymphocyte response was studied. Protection
against lethal virus challenge was successfully achieved with
a chimeric protein containing a single, 9-aa T-cell epitope.
MATERIALS AND METHODS
Mice. BALB/c mice (H-2d haplotype) were bred in our
colony under specific-pathogen-free conditions.
Cells. Third-passage mouse embryo fibroblasts were used
for infection with MCMV to produce target cells and for
determination of virus titers. KD2SV, a simian virus 40-
transformed kidney fibroblast line established from B10.D2
mice (H-2d haplotype) (14), was used for infection with
recombinant vaccinia viruses to produce target cells.
Viruses. Purified, tissue-culture-grown MCMV of strain
Smith (VR-194; American Type Culture Collection, Rock-
ville, Md.) was used for production of target cells, for
generation of CTL, and for infection of mice in adoptive
transfer experiments. Challenge infection of immunocompe-
tent vaccinated mice was performed with virulent MCMV
isolated from the salivary glands of infected mice (11).
Recombinant vaccinia viruses. The recombinant vaccinia
virus MCMV-ieI-VAC encodes pp89 (25). The recombinant
MCMV-ieI(AF)-VAC encodes a deletion mutant of pp89 that
lacks amino acids 136 to 249 and therefore does not contain
any epitope recognized by BALB/c CTL (7).
(i) Deletion of TEl epitope pentameric core: A5-mer con-
struct. The nucleotide sequence encoding the IEl epitope
core (170-HFMPT-174) was deleted by site-directed muta-
genesis in M13mpl9 using the oligonucleotide 5'GCC CTA
GAT TTG GGT ACA TG3' and following the procedure
described by Zoller and Smith (27) as modified by Volkmer
et al. (25). Oligonucleotides were synthesized in an Applied
Biosystems oligonucleotide synthesizer (model 381A). Mu-
tagenesis was controlled by DNA sequencing. The mutated
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pp89 sequence was cloned downstream of the vaccinia virus
P7.5 early/late promoter into the vaccinia virus recombina-
tion vector pCS43 (1). Recombinant vaccinia viruses were
produced as described earlier (25).
(ii) Integration of IEl epitope sequences in deletion mutant
AF. To reintegrate IEI epitope sequences at a different
position in pp89, we chose deletion mutant AF, which lacks
the IE1 epitope. A unique BglII site in the 3' end of the AF
reading frame, at codon 553 (7, 12), was used as the insertion
site for synthetic oligonucleotides. The oligonucleotides
contained IEl epitope sequences and were flanked by a
BamHI site at their 5' end and by an EcoRI and a BgII site
at their 3' end. The oligonucleotide encoding the 7-mer
sequence was integrated for a second time in the reverse
orientation. All constructs were sequenced and then recom-
bined into vaccinia virus.
(iii) Integration of pp89 IEl epitope sequences into HBcAg.
An AvaI site located 5 codons upstream of the termination
codon of the hepatitis B virus core antigen (HBcAg) gene of
hepatitis B virus type 2 (9) was used for the insertion of
synthetic oligonucleotides encoding IEl epitope sequences.
Sequence analysis was performed before recombination into
vaccinia virus.
Cytolytic assays. (i) Target cells. Enhanced and selective
expression ofMCMV immediate-early gene products includ-
ing pp89 was achieved as described previously (16). For
expression of foreign protein antigens by recombinant vac-
cinia viruses, KD2SV cells were infected with 5 to 20 PFU
per cell for 16 h. Target cells were trypsinized and labeled for
90 min with Na251CrO4, and a standard 3-h cytolytic assay
was performed with 1,000 target cells and graded numbers of
cytolytic effector cells in twofold or threefold dilution steps.
Data represent the mean percentage of specific lysis from
three replicate cultures. For preparing target cells with
exogenously added peptides, 105 cells were incubated with
peptides at different concentrations in a volume of 50 Fl for
1 h at room temperature after the 51Cr labeling, and excess
unbound peptide was washed off before effector cells were
added.
(ii) Cytolytic effector cells. pp89-specific polyclonal CTL
were generated by in vitro restimulation with purified
MCMV of spleen cells from mice that had been intrave-
nously infected with 108 PFU of recombinant MCMV-ieI-
VAC 3 weeks before (7).
Western blot (immunoblot) analysis. KD2SV cells were
infected with 5 to 20 PFU of the recombinant vaccinia
viruses per cell for 16 h, lysed in sample buffer for sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, sepa-
rated by electrophoresis, and blotted onto nitrocellulose
membranes. For detection of recombinant pp89 proteins,
blots were incubated with a rabbit antiserum raised against
amino acid residues 34 to 53 of pp89 (7). For detection of
recombinant HBcAg proteins, a human patient serum sam-
ple reactive with HBcAg was used.
Adoptive transfer. Donor mice used as source of CD8+ T
lymphocytes were immunized with MCMV (2 x 105 PFU
intraperitoneally) or with recombinant vaccinia viruses (1 x
108 PFU intravenously) at least 3 weeks earlier. Splenic
CD8+ T lymphocytes were enriched by passage through a
nylon wool column and subsequent treatment with antibody
to CD4 and complement (20), and their in vivo antiviral
activity was tested by adoptive transfer into sublethally
irradiated (5.5 Gy, corresponding to a 50% lethal dose [LD50]
over an observation period of 30 days) and MCMV-infected
(2 x 105 PFU in the footpad) 9-week-old recipient BALB/c
mice as described previously (20). Twelve days after trans-
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FIG. 1. IEl epitope sequences are essential for the recognition of
pp89 by BALB/c CTL. Spleen cells from mice primed with the
recombinant vaccinia virus MCMV-ieI-VAC, encoding pp89 (left
panel), or with the recombinant AS-mer, encoding a deletion mutant
of pp89 that lacks the IEl epitope pentameric core (right panel),
were restimulated in vitro with MCMV and tested in a cytolytic
assay for recognition of MCMV-infected target cells expressing
pp89 (A) and of target cells infected with MCMV-iel-VAC (0) or
A5-mer (0). Cells infected with wild-type vaccinia virus (x) and
uninfected target cells (A) provided the negative controls. E:T
Ratio, effector-to-target clel ratio.
fer, MCMV titers in spleens of individual recipient mice
were determined.
Protection against lethal challenge infection. Mice were
vaccinated i.v. with 108 PFU of recombinant vaccinia vi-
ruses, and 3 weeks later, they were challenged i.p. with 3
LD50s of virulent salivary gland-derived MCMV (11).
RESULTS
lE1 epitope sequences are essential for recognition of pp89
by BALB/c CTL. To test whether single epitopes recognized
by CTL can replace the whole protein for induction of
protective immunity in vivo, knowledge of the number of
epitopes present in the protein is important. Previous results
showed that the region of pp89 between amino acid residues
136 and 249 was required for recognition of the protein by
CTL (7). Although the IEl epitope presented by Ld has been
positively identified within this region (6, 7), it was not
excluded that other epitopes exist. To detect epitopes be-
sides IEl, a deletion mutant of pp89, named A5-mer, was
constructed and recombined into vaccinia virus. This recom-
binant lacked just the pentameric core HFMPT of the TEl
epitope. When it was used to infect target cells expressing all
H-2d class I molecules, the mutant protein was not recog-
nized by polyclonal pp89-specific CTL from BALB/c mice
primed with the recombinant MCMV-ieI-VAC encoding
authentic pp89 (Fig. 1, left panel). In an attempt to increase
the frequency of CTL specific for putative epitopes in the
mutant protein, we primed mice with the A5-mer recombi-
nant. As shown in Fig. 1 (right panel), no CTL that recog-
nized the A5-mer protein or authentic pp89 could be de-
tected. Likewise, in vitro restimulation with the A5-mer
recombinant of memory T lymphocytes from mice that were
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latently infected with MCMV could not be achieved (data
not shown). It was thus concluded that IEl epitope se-
quences are essential for the recognition of pp89 by BALB/c
CTL.
A 9-aa IEl epitope sequence is efficiently presented to CTL
even after shifting to a different location of pp89. The protec-
tive capacity of pp89 is based on the function of CD8+ T
lymphocytes (11). Since IEl is the only epitope recognized
by CTL in pp89, it can be expected that it is sufficient for the
induction of protective immunity. Before selecting an TEl
sequence of a given length for testing this hypothesis, it
should be recalled that synthetic TEl epitope sequences of
different lengths show considerably different antigenicities
for CTL clone IEl (19). In this respect, BALB/c polyclonal
pp89-specific CTL exhibit a fine specificity similar to that
of CTL clone TEl, since the synthetic nonapeptide
YPHFMPTNL constituted the optimal antigenic peptide,
giving half-maximal recognition at a concentration as low as
10-1° M. The synthetic heptapeptide PHFMPTN and the
pentapeptide core HFMIT retained antigenicity, being de-
tected at concentrations of 10-6 and 10' M, respectively
(data not shown).
These three IEl epitope sequences were chosen to inves-
tigate their ability to be presented when expressed from
intracellularly synthesized chimeric proteins. To this end,
IE1 epitope sequences of 9, 7, and 5 aa were inserted close
to the C terminus of deletion mutant AF of pp89, which lacks
the original IEl epitope (7) (Fig. 2A). DNA constructs were
confirmed by sequencing (Fig. 2B) and then recombined into
vaccinia virus. Expression of the chimeric proteins was
confirmed by Western blot analysis (Fig. 3A).
Antigenicity of target cells infected with the different
recombinants was tested by using pp89-specific polyclonal
CTL as effector cells. As shown in Fig. 4A, target cells
infected with the recombinant virus encoding the AF/9-mer
chimeric protein were recognized by CTL, thus indicating
that the TEl epitope was correctly processed and presented
even when inserted into a different position of the same
protein.
The 7-mer and 5-mer constructs were, however, not
recognized (Fig. 4A). The same conclusion was reached
when mice were immunized with the different recombinant
viruses and their spleen cells were tested for the presence of
pp89-specific CTL after selective in vitro restimulation with
MCMV (data not shown). Additional confirmation also came
from experiments in which the different recombinants were
used for in vitro restimulation of pp89-specific memory CTL
(data not shown). From all this evidence, it was concluded
that IEl epitope sequences shorter than 9 aa were not
detectably presented from chimeric AF proteins, while the
9-mer was presented as efficiently as from the authentic
location in pp89.
IE1 epitope is also presented from an unrelated, HBcAg-
based chimeric protein. To test the protective capacity of the
IEl epitope in the absence of separate potential pp89-
derived helper-T-cell epitopes, we inserted IEI sequences of
9 and 7 aa into an unrelated protein, HBcAg. Recombinant
vaccinia viruses were produced, and the sequence (Fig. 2)
and expression (Fig. 3B) of the chimeric proteins were
confirmed. As with the AF-based recombinants, when rec-
ognition by CTL of cells expressing the chimeric proteins
was tested, the 9-mer construct was recognized, whereas the
7-mer was not (Fig. 4B). Thus, the same epitope presenta-
tion hierarchy was found regardless of the protein back-
ground. In addition, the fact that the nonameric IEl epitope
could be shifted not only to a different position in the same
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pp89 FDNVQ LGRLM YDMYP HFMPT NLGPS EKRVW HSYVG|
| 5mer |FDNVQ LGRLM4 YDMYP ---NLGPS EKRVW MSYVG|
AF/9mer lmtsp vlqpt trsYP HFMPT NLeLr lataa assgt
HBcAg/9mer rsqsp rrrrs qsrYP HFMPT NLsre sqc.
HBcAg/A,-9mer-A, rrrrs qsraa fAiYP HFKPT NLaa aare sqc.
aF/7zer slmts pvlqp ttrsP HFMPT Nefrs efisg hevwg
HBcAg/7mer rrsqs prrrr sqsrP HFMPT Nares qc.HBcAg/A-7mer-A rsqsp rrrrs qsraP HFMPT Nasre sqc.
A F/5mer | fslmt spvlq pttrs HFMPT efrsa taaas sgtap|
HBcAg/A,-5mer-A,| rsqsp rrrrs qsraa HFMPT a2are sqc. l
FIG. 2. Schematic representation (A) and amino acid sequence
(B) of pp89 and chimeric proteins. (A) Proteins are drawn as long
open boxes, and numbers above them indicate amino acid positions.
IEl epitope sequences are shown as closed boxes not drawn to the
same scale as the proteins, and their length and the presence of
flanking alanine residues are indicated on their right. (B) Amino
acids are shown in the one-letter code. Capitals indicate native pp89
sequences. Dashes indicate deleted amino acids. Underlined lower-
case letters refer to amino acids encoded by linker sequences for
restriction endonucleases introduced during the construction of the
chimeric genes. Lowercase indicates sequences from the vector
proteins. Chimeric proteins are named, citing first the vector protein
and then the length of the IEl sequence encoded. Where alanine
residues flank IEl sequences, their number on each side of the
epitope is indicated.
protein but also to an unrelated protein suggested that the
requirements for its processing and presentation are not very
stringent.
Correlation between antigenic potency of synthetic peptides
and recognition by CTL of chimeric proteins expressing IEl
epitope sequences. The lack of recognition by CTL of the
5-mer sequence in AF and of the 7-mer sequence in both
chimeric proteins tested could be explained either by their
lower antigenicity compared with the 9-mer (19) or by their
shorter length, which could bring the antigenic core into
closer proximity to potentially disturbing amino acid resi-
dues derived from the vector. To discriminate between these
alternatives, LEl epitope sequences of different lengths and
antigenicities were made to reach a common final length
of 9 aa by flanking them with alanine residues. Alanine
was chosen because it has the shortest side chain among
the amino acids. The feasibility of this approach was first
tested at the level of synthetic peptides. The sequence
A-PHFMPTN-A has the length of the 9-mer but only the 7 aa
of the IE1 epitope present in the 7-mer (PHFMPTN). When
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FIG. 3. Expression of pp89 and chimeric proteins containing IEl
epitope sequences in cells infected with recombinant vaccinia
viruses. Western blot analysis with pp89-specific (A) or HBcAg-
specific (B) antiserum of cells infected with the following recombi-
nant viruses (see Fig. 3 for abbreviations): (A) lane a, MCMV-iel-
VAC, encoding pp89; lane b, A5-mer; lane c, AF; lane d, AF/9-mer;
lane e, AF/7-mer; lane f, AF/5-mer; (B) lane a, HBcAg; lane b,
HBcAg/9-mer; lane c, HBcAg/A5-9-mer-A5; lane d, HBcAg/7-mer;
lane e, HBcAg/A-7-mer-A; lane f, HBcAg/A2-5-mer-A2. K, kilodal-
tons.
tested as a synthetic peptide, the alanine-flanked 7-mer had
a slightly higher antigenic potency than the original 7-mer.
Similarly, the antigenicity of the peptide AA-HFMPT-AA
was comparable to that of HFMPT (Table 1).
Once it was found that flanking alanine residues did not
reduce the antigenic properties of IEl synthetic peptides, the
alanine-flanked 7-mer and 5-mer sequences were inserted
into HBcAg to test whether these sequences could be
presented from intracellularly synthesized proteins. Cells
infected with the corresponding recombinant vaccinia vi-
50
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FIG. 4. The 9-aa IEl epitope sequence is efficiently presented
from intracellularly synthesized chimeric proteins. Recognition by
pp89-specific CTL in a cytolytic assay of target cells infected with
recombinant vaccinia viruses encoding chimeric proteins that con-
tain IEl epitope sequences. IEl epitope sequences were inserted
into pp89 AF (A) or into HBcAg (B and C). Encoded lEl sequences
are as follows: A, 9-mer; 0, 7-mer (A and B); V, 5-mer (A); A,
A5-9-mer-A5; 0, A-7-mer-A (C); V, A2-5-mer-A2 (C). Controls
include cells infected with the recombinant viruses encoding authen-
tic pp89 (0) and the vector proteins AF (0) and HBcAg (x). E:T
Ratio, effector-to-target cell ratio.
TABLE 1. Adjustment to nonapeptide length by symmetric
alanine flanking
Peptide Threshold of Plateau of
sequence detectiona detectiona
YPHFMPTNL -11 to -10 -9 to -7
PHFMPTN -8 to -7 -4
APHFMPTNA -9 to -8 -5 to -4
HFMPT -5 -4 to -3
AAHFMPTAA -6 to -5 -4
a Recognition of peptide-incubated LILV target fibroblasts by CTL clone
IEl in a cytolytic assay. Peptide concentration is given in log molar units.
ruses were again not recognized by CTL (Fig. 4C), even
though all inserts were now 9 aa long. Flanking alanine
residues did not generally affect intracellular processing or
presentation in a negative manner, since a chimeric protein
carrying the 9-mer flanked even by five alanines in HBcAg
was recognized by CTL to the same extent as was the 9-mer
construct (Fig. 4C). Thus, the short length was not the
determining factor for the lack of presentation of TEl 7-mer
and 5-mer sequences from intracellularly synthesized chi-
meric proteins; rather, the lower antigenicity compared with
the 9-mer was the deciding factor.
Induction of protection in vivo with the nonameric lE1
epitope sequence. Results shown so far indicate that the
9-mer TEl epitope sequence is as antigenic when presented
from chimeric proteins as the authentic pp89. We asked
whether this similarity also extended to the protective ca-
pacity in vivo, that is, whether the recombinant virus encod-
ing the 9-mer in a chimeric protein could be used as an
epitope vaccine. To exclude a contribution of MCMV se-
quences other than the tested TEl epitope, we used the
HBcAg-based chimeric protein.
Induction of protective immunity in vivo was tested by
priming mice with the different recombinant viruses followed
by a challenge with a lethal dose of MCMV (Fig. 5). A high
percentage of animals primed with the recombinant MCMV-
ieI-VAC encoding the whole pp89 protein were protected
80-
60-
0
u
o 40-
20-
Immunization: pp89 pp89 HBcAg HBcAg/
ASmer /9mer
FIG. 5. Protection against lethal MCMV infection in mice immu-
nized with pp89 lEl epitope sequences. Mice were immunized with
recombinant vaccinia viruses encoding the indicated proteins. Three
weeks later they were challenged with 3 LD50s of MCMV. Protec-
tion, indicated on the ordinate, is calculated as the percentage of
surviving mice of the total tested. The actual number of mice in each
group (survivors/tested) is indicated on top of each column. Data are
compiled from nine independent experiments, three of which in-
cluded the A5-mer recombinant.
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FIG. 6. Antiviral effect of CD8+ T lymphocytes sensitized with
pp89 IEl epitope sequences. Donor mice were immunized with
MCMV or with recombinant vaccinia viruses encoding the indicated
proteins. Splenic memory T lymphocytes were purified through a
nylon wool column followed by depletion of CD4+ cells. CD8+ T
lymphocytes thus obtained were adoptively transferred into irradi-
ated and MCMV-infected recipient mice. Dots represent MCMV
titers in the spleens of individual recipients determined at day 12
after infection. Bars represent median titer values in each group.
DL, detection limit.
against death, as described previously (11). Lack of the IEl
epitope pentameric core in the AS-mer recombinant resulted
in the complete inability to induce protective immunity,
correlating with the lack of recognition by CTL of cells
infected with this recombinant virus in vitro. The finding that
priming with HBcAg/9-mer conferred protection against
lethal challenge with MCMV confirmed that induction of
protection was a property of the IE1 epitope and thus
showed the potential of the recombinant virus encoding the
9-mer to function as a T-cell epitope vaccine.
The efficacy of the recombinant vaccine was also tested by
adoptive transfer of primed T lymphocytes into irradiated
and lethally infected recipient mice (Fig. 6). This experimen-
tal system reflects more closely the clinical situation, in
which infection of immunosuppressed patients with human
CMV is more relevant than acute infection of immunocom-
petent individuals with a high dose of virus. In this model,
the antiviral activity of transferred CD8+ T lymphocytes
from donors primed with MCMV or with pp89 is reflected by
a reduction of MCMV titers in different organs of infected
recipient mice (11, 20) (Fig. 6). As before, removal of the IEl
pentameric core prevented induction of antiviral CD8+ T
lymphocytes by the AS-mer recombinant. Priming of the
donor mice with the vaccinia virus recombinant encoding
HBcAg alone did not induce antiviral T lymphocytes either.
In contrast, virus titers in the spleens of the infected recip-
ient mice were reduced after transfer of CD8+ T lympho-
cytes from mice primed with the HBcAg/9-mer recombinant
to the same extent as in those mice that had received cells
from donors primed with pp89. These results confirm the
data from the challenge experiments and, taken together,
demonstrate the induction of antiviral CD8+ T lymphocytes
and protection against lethal infection by a recombinant
vaccine containing a single nonameric T-cell epitope of the
MCMV regulatory protein pp89.
DISCUSSION
CD8+ T lymphocytes mediate protection against lethal
MCMV infection after vaccination of mice with a recombi-
nant vaccinia virus encoding a single MCMV gene product,
the nonstructural nuclear phosphoprotein pp89, which is
expressed in the immediate-early phase of the MCMV rep-
lication cycle (11). In the present report, we extend this
finding by showing that a chimeric protein carrying a se-
quence of only 9 aa, which constitutes the only epitope
recognized by BALB/c CTL in pp89, induces a degree of
protection similar to that afforded by the entire pp89 protein.
In the lymphocytic choriomeningitis virus model, protec-
tion has been recently shown using truncated viral proteins.
However, when an isolated CTL epitope was expressed in
vaccinia virus, it was recognized in vitro by CTL but failed
to induce T cells in vivo. A need for increased epitope
expression or additional T-helper epitopes required for CTL
induction was postulated (13). In our case, however, inclu-
sion of separate sequences from pp89 or from any other
MCMV protein for recognition by helper T lymphocytes was
not required either for the induction or for the antiviral
activity of CD8+ T lymphocytes. These results do not
indicate any difference in the viral sequence requirements
for CTL induction and recognition and thus encourage the
design of multivalent vaccines that include short CTL
epitopes from several viral proteins, as well as linear
epitopes recognized by antibodies.
This is the first example of successful induction of protec-
tive cellular immunity using as a carrier HBcAg, a protein
utilized to date only for the induction of antibodies to foreign
epitopes (2). The finding that a very short sequence of pp89
can substitute for the whole protein opens the possibility of
exploring antigen presentation from different carrier vectors,
including those with a very limited capacity for insertion of
foreign sequences. This possibility is substantiated by the
finding that the IEl epitope nonameric sequence was effi-
ciently processed and presented from the two chimeric
proteins tested.
To evaluate the antigenicity required from a candidate
epitope for a recombinant vaccine, IEl epitope sequences of
different lengths and antigenicities were flanked by alanine
residues to reach a common final length of 9 aa. The
additional flanking alanines apparently did not affect either
intracellular processing of chimeric proteins or presentation
of synthetic peptides by surface class I molecules. Compar-
ison of IEl sequences of the same length which were
inserted into the same genetic environment revealed that
the IEl epitope 7-mer (A-PHFMPTN-A) and 5-mer (AA-
HFMPT-AA) sequences could not be recognized by CTL
when expressed from intracellularly synthesized chimeric
proteins, whereas the 9-mer (YPHEMPTNL) was recog-
nized. This correlates with the lower antigenicity of the
7-mer and 5-mer synthetic peptides compared with that of
the 9-mer. Thus, only IEl antigenic sequences that as
synthetic peptides were recognized at concentrations below
10-6 M were also detectable by CTL when presented from
intracellularly synthesized proteins. Moreover, only such
sequences could trigger a pp89-specific immune response in
vivo. More generally, our results suggest the existence of an
antigenicity threshold that must be reached for the presen-
tation of antigenic peptides from intracellularly synthesized
proteins. This may explain why some sequences are anti-
genic as synthetic peptides but are not recognized after
intracellular antigen processing in presentation by major
histocompatibility complex class I (3) or class II (4, 8)
molecules.
The finding that a 9-mer sequence is sufficient for antigen
presentation and induction of protective immunity agrees
with recent data on naturally processed peptides isolated
I 6 t--0
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from virus-infected cells, for which lengths of 8 and 9 aa
have been found (21, 24). We suggest that the information
obtained with synthetic peptides concerning the length and
the antigenic potency of optimal antigenic sequences may
have a predictive value also in other systems for the suc-
cessful construction of recombinant vaccines containing
short CTL epitope sequences.
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